Development of Carmustine Loaded PLGA-PEG Conjugates for Nose to Brain Targeting

Intranasal drug delivery is a promising route for drug delivery directly to the brain for acute or chronic treatments. A direct route to the brain offers a rapid approach to delivering drugs to the central nervous system without using the parenteral route. Carmustine is a nitrosourea used to treat brain tumors, multiple myeloma, lymphoma, and Hodgkin's disease but its use is limited by a very little half-life in the body fluids. The nanoparticles have shown great potential to overcome problems related to shorten shelf life. The present study aims to develop a nose-to-brain delivery system for Carmustine to prevent degradation and prolong it's bioavailability at the target site. It has shown that the nanoparticles have uniform size and shape and were found to be 231 +/- 21.2 nm with 0.128 PDI. The system has stabilized with sufficient surface charge and the zeta potential of the system was found to be -21.2 +/- 2.3 mV. After 24 h, cumulative drug release from the prepared system was found to be the maximum release of around 96.69 +/- 3.38 in the phosphate buffer pH 6.8.